-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma - 2 year(s) ago
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible #MultipleMyeloma, which he presented at #ASCO2023. Learn more: https://t.co/EHhy2LNZbC @ASCO #OncologyNews https://t.co/Yz6T8kdxfN
-
-
Mashup Score: 0Continued CRC Research Informs Later-Line Disease Management - 2 year(s) ago
Howard S. Hochster, MD, highlights key updates in CRC research and management from the 2023 ASCO Annual Meeting, including findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tumor placement and response to neoadjuvant chemotherapy can help clarify and personalize later-line treatment approaches in CRC. @HH_Oncodr @RWJBarnabas @ASCO #ASCO2023 #crcsm https://t.co/hQv2v5m4yy https://t.co/PugEOWXiYy
-
-
Mashup Score: 0Continued CRC Research Informs Later-Line Disease Management - 2 year(s) ago
Howard S. Hochster, MD, highlights key updates in CRC research and management from the 2023 ASCO Annual Meeting, including findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Howard S. Hochster, MD, highlights findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study. @HH_Oncodr @RWJBarnabas @ASCO #ASCO2023 #crcsm https://t.co/hQv2v5m4yy
-
-
Mashup Score: 0Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer - 2 year(s) ago
Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Following the 2023 ASCO Annual Meeting, experts on HR+/HER2- breast cancer discuss the evolving treatment landscape and data updates on frontline and later-line therapies. #breastcancer #ASCO2023 https://t.co/T1RwfuNF1F
-
-
Mashup Score: 0Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future - 2 year(s) ago
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Although KEYNOTE-789 missed both primary end points, patients with TKI-resistant, EGFR-mutated metastatic NSCLC had numerically prolonged survival with pemetrexed and chemotherapy with pembrolizumab. @ASCO #ASCO23 #ASCO2023 #lcsm https://t.co/QtBzIot15m https://t.co/peFutTiNo8
-
-
Mashup Score: 1
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how it may address an unmet clinical need. @theNCI @ASCO #ASCO23 #ASCO2023 https://t.co/hkneFd0k1B
-
-
Mashup Score: 0RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma - 2 year(s) ago
Mitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors. @MiteshBorad @MayoClinic @ASCO #ASCO2023 #oncology #medtwitter https://t.co/B6if3y0BWi
-
-
Mashup Score: 0Notable Advancements in Treatment for ALL - 2 year(s) ago
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Experts provide updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023. #ASCO2023 #leusm https://t.co/2WpxNzxCu7
-
-
Mashup Score: 0Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future - 2 year(s) ago
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial, as well as unmet needs in patients with TKI-resistant, EGFR-mutated metastatic NSCLC. @ASCO #ASCO23 #ASCO2023 #lcsm https://t.co/LIee670eDn
-
Research presented at #ASCO2023 focused on plasma miR-371a-3p, a potential biomarker demonstrating high sensitivity and specificity in advanced non-teratoma testicular germ cell #tumors. https://t.co/of9gruGIO5 #TesticularCancer https://t.co/rbTfrAHFsC